Calcium channel blockers revisited by Cheung, BMY & Kumana, CR
Title Calcium channel blockers revisited
Author(s) Cheung, BMY; Kumana, CR
Citation Hong Kong Medical Journal, 2002, v. 8 n. 4, p. 300-301
Issued Date 2002
URL http://hdl.handle.net/10722/45135
Rights Creative Commons: Attribution 3.0 Hong Kong License
300      Hong Kong Med J Vol 8 No 4 August 2002
COMMENTARY
Calcium channel blockers (CCBs) are a major class of drugs
used in the treatment of hypertension, angina, and cardiac
arrhythmias. Among the CCBs, there is much heterogen-
eity in terms of their effect on heart rate, cardiac contractility,
peripheral vascular tone, and with respect to half-life. The
CCBs can be broadly divided into the dihydropyridines
(eg nifedipine) and the non-dihydropyridines (eg verapamil).
Short-acting dihydropyridines, such as immediate-release
nifedipine, cause a rapid decrease in blood pressure and
a reflex tachycardia as they do not suppress heart rate.
Long-acting formulations and CCBs with longer half-lives
were thus developed to overcome large fluctuations in blood
pressure.
Although CCBs are undoubtedly effective in lowering
blood pressure, until the last few years, there have not
been substantial clinical outcome data demonstrating their
impact on cardiovascular events. Indeed, earlier case-
control studies from Furberg et al1 and others raised doubts
about the safety of this class of drugs,1-4 which were ap-
proved and marketed on the basis of their effect on blood
pressure as a surrogate end-point. These studies suggested
that CCBs were associated with increased risk of myocar-
dial infarction,1 cancer,2 and gastrointestinal haemorrhage.3
The lack of prospective data from large clinical trials
meant that these doubts were hard to dismiss.
Fortunately, in the last few years, several important
clinical trials—STONE (Shanghai Trial of Nifedipine in
the Elderly),5 Syst-Eur (The Systolic Hypertension in
Europe),6 and Syst-China (Systolic Hypertension in
China)7—involving CCBs, have been completed and
published. On the whole, these have been reassuring with
regard to the safety of CCBs. The incidence of strokes was
reduced in these trials. The major question is, however, not
whether CCBs are better than placebo, since diuretics and
beta-blockers are already proven therapy for hyperten-
sion, but whether or not CCBs are equivalent to diuretics
and beta-blockers. The STOP-2 (Swedish Trial in Old
Patients with Hypertension-2 study),8 NORDIL (Nordic
Diltiazem study),9 and INSIGHT (Intervention as a Goal
in Hypertension Treatment10) trials addressed this question
with head-to-head comparisons of drug classes. In essence,
CCBs were not shown to be significantly better or worse
than older treatments. Whilst CCBs have been vindicated
to a large extent, the fact is that they tend to be more
expensive than diuretics and beta-blockers. From a public
health perspective therefore, one must question whether it
is justifiable to prescribe CCBs rather than cheaper,
older treatments.
The WHO-ISH (World Health Organization-
International Society of Hypertension) guidelines on the
management of hypertension published in 1999 endorsed
the use of any of six classes of antihypertensive drugs,
including CCBs, as first-line agents.11 This differs from the
American Joint National Committee-VI guidelines which
continue to recommend diuretics and beta-blockers as
first-line treatment because of their demonstrated efficacy
in numerous trials.12 Pooling recent clinical trials involving
comparisons of CCBs with other classes have shown a
disturbing pattern.13,14 Whereas CCBs appeared slightly
superior to angiotensin-converting enzyme inhibitors
(ACEIs) in the prevention of strokes, and no difference in
overall mortality between the two classes was seen, CCBs
appeared notably inferior to ACEIs in the prevention of
coronary events.13 These findings are consistent with the
demonstrated beneficial effect of beta-blockers and ACEIs
after myocardial infarction and in heart failure, and the
failure to demonstrate such benefits of CCBs. This has led
to the suggestion that CCBs should not be the first choice in
patients at cardiovascular risk unless multiple drugs are
needed to control their blood pressure.15
In this new decade, things have turned full circle.
Although CCBs regained favour when the placebo-
controlled trials were completed, with more clinical trial
data comparing different antihypertensive drug classes,
they have been found wanting. Interestingly, alpha-blockers
have also emerged as inferior agents to diuretics in the
ALLHAT (The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial) study.16
Though there was ‘more heat than light’ in the debate
over CCBs a few years ago, we now have hard clinical
evidence on which to base our judgements. From the
clinician’s point of view, CCBs will continue to be useful
for those patients primarily at risk of stroke rather than
coronary heart disease, and for those with severe hyper-
tension requiring combination therapy. For those with mild
hypertension requiring monotherapy, diuretics and beta-
blockers are proven and very cost-effective treatments; they
should be used unless contraindicated or not tolerated by
the patient. Angiotensin-converting enzyme inhibitors
should be considered, especially in the light of the HOPE
(Heart Outcomes Prevention Evaluation) study,17 for pa-
tients who have coronary artery disease, cerebrovascular
disease, peripheral vascular disease, or diabetes mellitus with
at least one other risk factor.
In the Far East where strokes are common and coronary
heart disease is less prevalent than in Caucasian popu-
lations, the benefits of CCBs may be more pronounced. In
terms of lowering of blood pressure, CCBs are very effect-
ive for Chinese patients.18-20 There has been a trend towards
lower blood pressure treatment targets, especially in pa-
tients with diabetes or nephropathy.11,12 The best way of
optimising blood pressure control is to use a combination
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of antihypertensive drugs. In this clinical scenario, CCBs
are useful and safe agents.
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